The risk of bleeding of triple therapy with vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: Facts and questions

Andrea Rubboli
Division of Cardiology and Cardiac Catheterization Laboratory, Ospedale Maggiore, 40133 Bologna, Italy

Abstract

Background Triple therapy (TT) with vitamin K-antagonists (VKA), aspirin and clopidogrel is the recommended antithrombotic treatment following percutaneous coronary intervention with stent implantation (PCI-S) in patients with an indication for oral anticoagulation. TT is associated with an increased risk of bleeding, but available evidence is flawed by important limitations, including the limited size and the retrospective design of most of the studies, as well as the rare reporting of the incidence of in-hospital bleeding and the treatment which was actually ongoing at the time of bleeding. Since the perceived high bleeding risk of TT may deny patients effective strategies, the determination of the true safety profile of TT is of paramount importance.

Methods All the 27 published studies where the incidence of bleeding at various time points during follow-up has been reported separately for patients on TT were reviewed, and the weakness of the data was analyzed.

Results The absolute incidence of major bleeding upon discharge at in-hospital, ≤ 1 month, 6 months, 12 months and ≥ 12 months was: 3.3% ± 1.9%, 5.1% ± 6.7%, 8.0% ± 5.2%, 9.0% ± 8.0, and 6.2% ± 7.8%, respectively, and not substantially different from that observed in previous studies with prolonged dual antiplatelet treatment with aspirin and clopidogrel.

Conclusions While waiting for the ongoing, large-scale, registries and clinical trials to clarify the few facts and to answer the many questions regarding the risk of bleeding of TT, this treatment should not be denied to patients with an indication for VKA undergoing PCI-S provided that the proper measures and cautions are implemented.

J Geriatr Cardiol 2011; 8: 207–214. doi: 10.3724/SP.J.1263.2011.00207

Keywords: percutaneous coronary intervention; stent; bleeding; oral anticoagulation; vitamin K antagonists; aspirin; clopidogrel

1 Introduction

Triple therapy (TT) with vitamin K-antagonists (VKA), aspirin and clopidogrel is the recommended antithrombotic treatment following percutaneous coronary intervention with stent implantation (PCI-S) in patients with an indication for oral anticoagulation, such as those with atrial fibrillation at moderate to high thromboembolic risk, mechanical heart valves, previous cardiogenic thromboembolism and recent deep vein thrombosis or pulmonary embolism.

Owing to the superior efficacy of VKA compared to dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in preventing thromboembolic and thrombotic complications in patients with atrial fibrillation and mechanical aortic valve, and owing to the superior efficacy of DAPT compared to VKA, with or without aspirin, in preventing adverse cardiac events following PCI-S, TT with VKA, aspirin and clopidogrel is regarded as the optimal antithrombotic regimen in patients with an indication for VKA undergoing PCI-S.

Previous studies and recent meta-analyses have indeed shown that TT is associated with the lowest incidence of stroke compared to DAPT or the combination of VKA and a single antiplatelet agent (either aspirin or clopidogrel). Such result, however, appears to come at the price of an increased incidence of bleeding complications during follow-up. These bleedings are mostly major, and appear to increase in rate as TT prolongs over time. Because of that, TT is often not prescribed to patients in whom it is indicated, and even when prescribed, it is maintained for duration shorter than optimal. In addition, drug-eluting stents are generally not implanted, owing to the need for prolonged clopidogrel, and hence TT administration. As a consequence of the reported increase in major bleeding complications with prolonged TT, treatments of proven efficacy, such as a 12-month course of clopidogrel after PCI-S for an acute coronary syndrome, regardless of whether a bare-metal or a drug-eluting stent has been implanted, or the implantation of a drug-eluting...
stent in a diabetic patient, especially in the presence of a long lesion in a small vessel, may be denied to patients in whom the highest benefit is anticipated.

As previously pointed out,[9,10] however, uncertainty still exists over whether the safety profile of TT is really suboptimal. The evidence on which this assumption is based, in fact, is in general of poor quality: most of the studies are retrospective, and the few prospective studies are generally small and by single-center.[1,10] Furthermore, outcome comparisons were carried out within the same study cohort only in a minority of studies, while in most of them either no comparison or comparison against contemporaneous populations of patients with no indication for oral anticoagulation undergoing PCI-S and receiving DAPT was performed.[1,10] Finally, only seldom the occurrence of anticoagulation undergoing PCI-S and receiving DAPT porary populations of patients with no indication for oral anticoagulation undergoing PCI-S and receiving DAPT were included.

The overall number of patients receiving TT in the published studies is 3,791 (Table 1). The indications for VKA are reported in 93% of the studies (Table 1). In five studies (19%), only patients with atrial fibrillation were included (Table 1). In the remaining studies, atrial fibrillation was the most frequent indication for VKA (mean 57%; range: 24%–84%), followed by prosthetic heart valves (mean 9%; range: 0%–25%) and previous stroke (mean: 3%; range: 0%–13%) (Table 1). The indications for PCI-S are reported in 78% of the studies (Table 1). While in one study (4%), ST-elevation myocardial infarction (STEMI) was the only indication for PCI-S, in the remaining the mean prevalence of STEMI, non-ST-elevation acute coronary syndromes and stable ischemic heart disease was 24% (range: 3%–57%), 40% (range: 0%–80%), and 36% (range: 0%–85%), respectively (Table 1).

Among the procedural variables which may influence the occurrence of in-hospital bleeding, the use of radial approach, glycoprotein IIb/IIIa inhibitors, and bridging strategies with heparin after temporary VKA withdrawal was reported in 44%, 63% and 22% of studies, respectively (Table 2). Apart from one study (4%) where the radial approach was used in all patients, in the remaining it was used on average in 28% (range: 0%–66%) of cases (Table 2). The mean use of glycoprotein IIb/IIIa inhibitors was 29% (range: 2.5%–61%), while that of heparin bridging strategies in the 96% of the studies where it was not used as the standard approach for all cases, was on average 36% (range: 0%–88%), (Table 2).

The time points at which data on the incidence of major bleeding during follow-up are available include: hospitalization (26% of studies), ≤ 1 month (15%), 6 months (19%), 12 months (41%), and ≥ 12 months (19%) (Table 3).

Similarly, minor bleedings were evaluated at ≤ 1 month (19% of studies), 6 months (7%), 12 months (7%), and ≥ 12 months (15%) (Table 3), respectively.

### 2 Methods

Various combinations of key words such as percutaneous coronary intervention, stent, oral anticoagulation, warfarin, antiplatelet agents were used for Medline search. All English language, full-text articles from January 2004 to December 2010 reporting safety outcomes in patients with indication for VKA treatment who underwent PCI-S were selected for this review. References from these publications were also reviewed. Data were abstracted from reported events in full-text articles. A total of 28 studies met the criteria. One study[11] was excluded owing to subsequent duplicate publication after inclusion of more patients, leaving therefore 27 studies available for the analysis.[12–38]
Table 1. Design, size and indications for VKA therapy and PCI-S in the various studies.

| Ref.                  | Year | Design                  | PTS (n) | TT PTS (n) | Indication for VKA (%) | Indication for PCI-S (%) |
|-----------------------|------|-------------------------|---------|------------|------------------------|-------------------------|
| Orford, et al[12]     | 2004 | Retrospective, 1-center | 66      | 66         | 39 25 6 30 12 28 60   |                         |
| Mattichak, et al[13]  | 2005 | Retrospective, 1-center | 82      | 40         | 43 8 0 49 100 0 0     |                         |
| Khurram, et al[14]    | 2006 | Retrospective, 1-center | 214     | 107        | 80 5 0 15 - - -       |                         |
| Konstantino, et al[15]| 2006 | Retrospective, multi-center | 2737   | 76         | - - - - - 57 41 2    |                         |
| Lip & Karpha[16]      | 2006 | Retrospective, 1-center | 35      | 6          | 100 0 0 0 31 63 6    |                         |
| Porter, et al[17]     | 2006 | Retrospective, 1-center | 180     | 180        | 37 6 5 52 46 37 17   |                         |
| Rubboli, et al[18]    | 2007 | Retrospective, 1-center | 49      | 20         | 60 8 6 26 31 29 40   |                         |
| Nguyen, et al[19]     | 2007 | Prospective, multi-center (post-hoc) | 800   | 580        | 40 3 0 57 61 39 0    |                         |
| DeEugenio, et al[20]  | 2007 | Retrospective, 1-center | 194     | 97         | 60 10 1 29 - - -     |                         |
| Karjalainen, et al[21]| 2007 | Retrospective, multi-center | 478   | 106        | 70 4 11 15 9 46 45   |                         |
| Manzano-Fernandez, et al[22]| 2008 | Retrospective, 1-center | 104    | 51         | 100 - - - 37 54 9    |                         |
| Rogacka, et al[23]    | 2008 | Retrospective, 1-center | 127    | 127        | 59 12 0 19 3 23 74   |                         |
| Rossini, et al[24]    | 2008 | Prospective, multi-center | 204   | 102        | 67 0 0 33 34 44 22   |                         |
| Sarafoff, et al[25]   | 2008 | Prospective, 1-center   | 515    | 306        | 67 17 0 16 - - -     |                         |
| Maegdefessel, et al[26]| 2008 | Retrospective, 1-center | 159    | 14         | 100 - - - 32 54 14   |                         |
| Haely, et al[27]      | 2009 | Prospective, multi-center (post-hoc) | 813   | 44         | - - - - - 16 41 43   |                         |
| Halbfass, et al[28]   | 2009 | Retrospective, 1-center | 117    | 53         | 100 - - - - - - -    |                         |
| Helft G, et al[29]    | 2009 | Prospective, 1-center   | 50     | 50         | 62 24 0 14 - - -     |                         |
| Rubboli, et al[30]    | 2009 | Prospective, multi-center | 163   | 111        | 84 9 2 5 21 51 28   |                         |
| Olson, et al[31]      | 2009 | Retrospective, 1-center | 514    | 175        | 24 1 1 74 - - -     |                         |
| Sambola, et al[32]    | 2009 | Prospective, multi-center | 405   | 278        | 65 17 1 17 - - -    |                         |
| Gilard, et al[33]     | 2009 | Prospective, multi-center | 359   | 125        | 63 18 0 19 8 39 53   |                         |
| Baber, et al[34]      | 2009 | Retrospective, 1-center | 454    | 170        | 45 6 8 41 - - -     |                         |
| Gao, et al[35]        | 2010 | Prospective, 1-center   | 622    | 142        | 100 - - - 12 - -     |                         |
| Uchida, et al[36]     | 2010 | Retrospective, 1-center | 575    | 50         | 58 6 10 26 12 18 60  |                         |
| Ziakas, et al[37]     | 2010 | Prospective, 1-center   | 56     | 56         | 66 9 13 12 - - -     |                         |
| Persson, et al[38]    | 2010 | Prospective, multi-center (post-hoc) | 27,972| 659        | - - - - - 10 80 10   |                         |

VKA: vitamin K-antagonists; PCI-S: percutaneous coronary intervention with stent implantation. TT: triple therapy; AF: atrial fibrillation; STEMI: ST-elevation myocardial infarction; NSTE-ACS: non ST-elevation acute coronary syndromes; PTS: patients.
The incidence of major and minor bleedings reported at the various time points of follow-up is reported in Table 4.

### 4 Discussion

As derived from the above data, definitive conclusions regarding the true safety of TT appear currently precluded. Apart from acknowledging that the overall population on TT which has been examined so far accounts for only about 4,000 patients, it must be noted that the analyses of the data were carried out retrospectively in 70% of the studies. While being subject to biases of various nature, the analyses did not correlate the bleeding event with the antithrombotic treatment actually ongoing at the time of complication. It is obvious that hemorrhagic complications occurring weeks or months after TT has been completed, cannot plausibly be attributed to this regimen, even though the analysis is carried out according to the initially assigned treatment. Indeed, in one study where such evaluation was carried out,\[27\] in half of patients who had been initially treated with TT clopidogrel had already been withdrawn at the time of bleeding, when only the combination of VKA and aspirin was ongoing.

The international normalized ratio (INR) value at the time of bleeding was reported in 5 studies (19%) for major...
bleeding and in 3 (11%) for minor bleedings. As regards major bleedings, the INR value was above the therapeutic range in 35% of patients (range 0%–100%). 

Also, no valuable information about the INR value at the time of bleeding, which has been shown to increase the risk of bleeding in patients on TT when above a cut-off value of 2.6,\(^\text{[24]}\) can be obtained from the available studies. While in one study all patients experiencing a major bleeding had the INR above the therapeutic range, in two studies major bleeding occurred regardless of the fact that the INR was within the therapeutic range (Table 3).

When focusing on the absolute incidence of major bleeding, an increase is apparent as follow-up prolongs (Table 4). While acknowledging that a more prolonged exposure to TT may intuitively be associated with and increased risk of bleeding, it should be noted once again that clear information about the ongoing treatment throughout the entire duration of follow-up is lacking. It is of note, however, that the in-hospital major bleeding rate was limited to about 3% (Table 3). Such figure is not substantially different from that reported in the overall population of patients undergoing PCI-S,\(^\text{[30]}\) therefore supporting the concept that TT in itself does not substantially impact on the incidence of early major bleeding. Further reduction of the in-hospital major bleeding rate may probably be obtained by more extensively using the radial approach, which has been shown to virtually eliminate the occurrence of bleeding at the vascular access site,\(^\text{[40]}\) and by further limiting the use of glycoprotein IIb/IIIa inhibitors, as well as of heparin bridging strategies following the (likely unnecessary) peri-procedural withdrawal of VKA, which both have been found associated with early hemorrhagic complications.\(^\text{[41,42]}\)

When examining the absolute incidence of major bleeding after discharge, it should be noted that the figures are not substantially different from those reported with DAPT, for example in the CREDO trial.\(^\text{[43]}\) In this study, the 1- and 12-month incidence of major bleeding was 4.7% and 8.8%, respectively, as compared to the average 5.1% and 9.0%, respectively, reported in patients receiving TT (Table 3). Subtracting the about 3% rate of in-hospital bleeding, which as previously mentioned has more to do with procedural variables than with TT itself, the true incidence of major bleeding during medium-term follow-up should be more likely in the reassuring order of 2% to 6%. Indeed, these figures have been reported in better quality studies, such those prospective and with a tight control of the INR which was also targeted to the lower end of the therapeutic range.\(^\text{[7,24,32,33]}\)

The lower incidence of major bleeding at a follow-up longer than 12 months may be explained by the limited number of studies reporting on that and by the variable duration of follow-up following the first year. Also not surprisingly is the non-linear course, as well as the variable absolute incidence, of minor bleedings because they often go undetected not inducing patients to seek medical attention.

### 4.1 Conclusions

TT with VKA, aspirin and clopidogrel is the recommended antithrombotic regimen following PCI-S in patients with an indication for VKA. Although being not clear-cut, current available evidence suggests that TT is associated with an increased risk of bleeding, apparently increasing as treatment prolongs. The absolute incidence of major bleeding at short- to medium-term follow-up appears not substantially different from that of DAPT, which however cannot be used alone in these patients because of the high risk of thromboembolic and thrombotic complications. Since major bleedings may be life threatening or may determine the withdrawal of one or more of the antithrombotic agents (therefore exposing patients to the risks of thromboembolism and/or stent thrombosis),\(^\text{[44]}\) and minor bleedings may induce physicians or patients to withdraw clopidogrel (again exposing patients to the potentially catastrophic stent thrombosis),\(^\text{[45]}\) it is prudent to limit the duration of TT for as short as possible, therefore using drug-eluting stents restrictively. However, when drug-eluting stent implantation is clinically necessary, the use of newer generation drug-eluting stents (especially polymer-free) that exhibit accelerated reendothelialization is preferred.\(^\text{[40]}\) This does not imply that patients receiving a newer generation drug-eluting stent should receive clopidogrel for < 12 months (current guidelines recommend at least 12 months of clopidogrel therapy following drug-eluting stent implantation),\(^\text{[46]}\) but rather the use of newer generation drug-eluting stent allows for the safer early interruption of clopidogrel if the need should arise.\(^\text{[10]}\) Finally, throughout TT, which should be limited to three to six months in VKA patients

Table 4. Incidence of major/minor bleeding at various time points of follow-up, data are presented as mean ± SD.

|                | Major bleeding (%) | Minor bleeding (%) |
|----------------|--------------------|--------------------|
| In-hospital    | 3.3 ± 1.9          | NR                 |
| ≤ 1 mo        | 5.1 ± 6.7          | 5.2 ± 3.1          |
| 6 mo          | 8.0 ± 5.2          | 13.1 ± 2.6         |
| 12 mo         | 9.0 ± 8.0          | 3.6 ± 5.1          |
| ≥ 12 mo       | 6.2 ± 7.8          | 9.5 ± 7.5          |

NR: not reported.
undergoing PCI-S in the context of an acute coronary syndrome (where current guidelines recommend 12 months of clopidogrel treatment),[47] the INR should be frequently and carefully monitored, along with being targeted at the lower end of the therapeutic range (i.e., 2.0 to 2.5 in patients with atrial fibrillation).,[23]

While waiting for the ongoing, large-scale, registries and clinical trials to clarify the few facts and to answer the many questions regarding the risk of bleeding of TT, this treatment should not be denied to patients with an indication for VKA undergoing PCI-S provided that the above mentioned measures and cautions are implemented.

References
1 Rubboli A, Halperin JL, Airaksinen KEJ, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary stenting. An expert consensus document with focus on atrial fibrillation. Am J Cardiol 2010; 105: 101–106.
2 Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Thromb Haemost 2010; 103: 13–28.
3 Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369–2429.
4 The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–1912.
5 Schilit A, von Bardeleben RS, Ehrlich A, et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res 2003; 109: 131–135.
6 Rubboli A, Milandri M, Castelvetri C, et al. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 2005; 104: 101–106.
7 Gao F, Zhou YJ, Wang ZJ, et al. Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation. Int J Cardiol 2010; 148: 96–101.
8 Zhao HJ, Zheng ZT, Wang ZH, et al. “Triple therapy” rather than “triple threat”: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139: 260–270.
9 Rubboli A, Halperin JL. Pro: “Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions”. Thromb Haemost 2008; 100: 752–753.
10 Rubboli A, Kovacic JC, Mehran R, et al. Coronary stent implantation in patients committed to long-term anticoagulation therapy: successfully navigating the treatment options. Chest 2011; 139: 981–987.
11 Rubboli A, Colletta M, Sangiorgio P, et al. Antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary artery stenting: safety and efficacy data from a single center. Ital Heart J 2004; 5: 919–925.
12 Orford JL, Fasseas P, Melby S, et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 2004; 147: 463–467.
13 Mattichak SJ, Reed PS, Gallagher MJ, et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Invasive Cardiol 2005; 18: 163–166.
14 Khurram Z, Chou E, Minutello R, et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 2006; 18: 162–164.
15 Konstantino Y, Iakobishvili Z, Porter A, et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology 2006; 106: 80–85.
16 Lip GYH, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. Chest 2006; 130: 1823–1827.
17 Porter A, Konstantino Y, Iakobishvili Z, et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2006; 68: 56–61.
18 Rubboli A, Colletta M, Herzfeld J, et al. Periprocedural and medium-term antithrombotic strategies in patients with an
indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis 2007; 18: 193–199.

Nguyen MC, Lim YL, Walton A, et al. Combining warfarin and antiplatelet therapy after coronary stenting in the global registry of acute coronary events: is it safe and effective to use just one antiplatelet agent? Eur Heart J 2007; 28: 1717–1722.

DeEugenio D, Kolman L, DeCaro M, et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy 2007; 27: 691–696.

Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 2007; 28: 726–732.

Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 2008; 134: 559–567.

Rogacka R, Chieffo A, Michev I, et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. J Am Coll Cardiol Intv 2008; 1: 56–61.

Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol 2008; 102: 1618–1623.

Saraffi N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. J Intern Med 2008; 264: 427–430.

Maegdefessel L, Schlatt A, Faerber J, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. Med Klin 2008; 103: 628–632.

Haeg C, Brunner-La Rocca HP, Kaiser C, et al. Early and late increased bleeding rates after angioplasty and stenting due to combined antplatelet and anticoagulant therapy. Eurointervention 2009; 5: 425–431.

Halbfass P, Janko S, Dorwarth U, et al. Dilemma of antithrombotic therapy in anticoagulated atrial fibrillation patients squeezed between thrombosis and bleeding events: a single-center experience. Europace 2009; 11: 957–960.

Helft G, Dambrin G, Zaman A, et al. Percutaneous coronary intervention in anticoagulated patients via radial artery access. Catheter Cardiovasc Interv 2009; 73: 44–47.

Rubboli A, Colletta M, Valencia J, et al. Periprocedural management and in-hospital outcome of patients with indication for oral anticoagulation undergoing coronary artery stenting. J Interv Cardiol 2009; 22: 390–397.

Olson KL, Delate T, Johnson SG, et al. Incidence of hemorrhage among anticoagulated patients receiving antiplatelet therapy after percutaneous coronary intervention. J Thromb Thrombolysis 2009; 29: 316–321.

Sambola A, Ferreira-González I, Angel J, et al. Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study. Heart 2009; 95: 1483–1488.

Gilard M, Blanchard D, Helft G, et al. Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting. Am J Cardiol 2009; 104: 338–342.

Baber U, Akhter M, Kothari S, et al. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol 2010; 22: 80–83.

Gao F, Zhou YJ, Wang ZJ, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J 2010; 74: 701–708.

Uchida Y, Mori F, Ogawa H, et al. Impact of anticoagulant therapy with dual antiplatelet therapy on prognosis after treatment with drug-eluting coronary stents. J Cardiol 2010; 55: 362–369.

Ziakas AG, Koskinas KC, Gavrildis S, et al. Radial versus femoral access for orally anticoagulated patients. Catheter Cardiovasc Interv 2010; 76: 493–499.

Persson J, Lindbaeck J, Hofman-Bang C, et al. Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. Eurointervention 2011; 6: 1046–1052.

Kinnirid TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930–935.

Rao SV, Ou F-S, Wang TY, et al. Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention. A report from the national cardiovascular data registry. J Am Coll Cardiol Intv 2008; 1: 379–386.

Lahtela H, Karjalainen PP, Niemelä M, et al. Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment? Thromb Haemost 2009; 102: 1227–1233.

Karjalainen PP, Vikman S, Niemelä M, et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29: 1001–1010.
43 Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. *JAMA* 2002; 288: 2411–2420.

44 Doyle BJ, Rihal CS, Gastineau DA, et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention. Implications for contemporary practice. *J Am Coll Cardiol* 2009; 53: 2019–2027.

45 Roy P, Bonello L, Torguson R, et al. Impact of “nuisance” bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. *Am J Cardiol* 2008; 102: 1614–1617.

46 Kushner FG, Hand M, Smith SC Jr, et al. 2009 Focused Updates: ACC/AHA Guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on percutaneous coronary intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2009; 120: 2271–2306.

47 Wijns W, Kohl P, Danchin N, et al. Guidelines on myocardial revascularization. *Eur Heart J* 2010; 31: 2501–2555.